MiNK Therapeutics (INKT) Other Non-Current Liabilities (2020 - 2026)
MiNK Therapeutics (INKT) posted Other Non-Current Liabilities of $284000.0 for Q1 2026, up 9553.3% sequentially from $2942.0 in Q3 2024.
MiNK Therapeutics (INKT) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $284000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $284000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284000.0 (changed N/A YoY) and the FY2023 annual result came in at $48072.0, down 55.69% from the prior year.
- Other Non-Current Liabilities advanced to $284000.0 in Q1 2026 per INKT's latest filing, from $2942.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $284000.0 in Q1 2026 and troughed at $2942.0 in Q3 2024.
- A 4-year average of $79417.3 and a median of $61130.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities surged 111.6% in 2022, then sank 95.4% in 2024.
- Over 4 years, Other Non-Current Liabilities stood at $108500.0 in 2022, then plunged by 55.69% to $48072.0 in 2023, then plunged by 93.88% to $2942.0 in 2024, then soared by 9553.3% to $284000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $284000.0, $2942.0, and $23280.0 for Q1 2026, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29,000.00 |
| Mar 31, 2026 | 284,000.00 |
| Sep 30, 2024 | 2,942.00 |
| Jun 30, 2024 | 23,280.00 |
| Mar 31, 2024 | 31,600.00 |
| Dec 31, 2023 | 48,072.00 |
| Sep 30, 2023 | 63,980.00 |
| Jun 30, 2023 | 79,342.00 |
| Mar 31, 2023 | 94,177.00 |
| Dec 31, 2022 | 108,500.00 |
| Sep 30, 2022 | 58,280.00 |
| Sep 30, 2021 | 27,543.00 |
| Dec 31, 2020 | 383,058.00 |